CTLA4 and melanoma: Furthermore, the administration of ticilimumab, a human monoclonal antibody against CTLA-4 can create sufficient anti-tumor responses against melanoma metastasizing to the subcutaneous tissues, lymph nodes, and lung through decreasing the number of Tregs and IL‐10 production and elevating IL-2 production by activated T cells [79].